Capsugel expands capabilities at Edinburgh facility

Capsugel, now a Lonza company, has expanded the clinical trial capabilities, as well as increased development and manufacturing capabilities for specialised drug products using liquid-filled hard capsule (LFHC) technology, at its Edinburgh facility.

“We are pleased to add API-in-capsule micro-dosing services to our clinical services offering at our Edinburgh facility,” said Jane Fraser, site head at Capsugel’s Edinburgh facility. “By adding new Xcelodose-based micro-dosing capabilities to our traditional liquid-filled hard capsule technology and high-potency capabilities, we are providing our customers with industry-leading solutions for rapid feasibility assessments and early stage clinical evaluations for their drug pipelines.”

The company’s expansion includes an enhancement of its micro-dosing services offering for early-phase cGMP manufacturing; a combination of its proprietary Xcelodose Precision Powder Micro-Dosing Systems with powder-in-capsule/powder in bottle (PIC/PIB) expertise to provide rapid product assessment and Phase I-II clinical trial material manufacture; and new Xcelodose 600S equipment.

Additionally, the facility will have expanded high-containment capabilities for handling highly potent and cytotoxic compounds at all stages of product development and manufacturing.

“As highly potent and cytotoxic drugs become increasingly prevalent in the drug development pipeline, our customers are turning to us for LFHC technology, specialized high-containment facilities and expertise that complies with heightened regulatory and operational requirements,” Fraser said. “Capsugel’s customers benefit from working with one partner to manage their drug product pipeline from bench to full commercial scale — resulting in faster development times and reduced risk, among other benefits.”